Video

Dr. Sonbol on the Role of Pembrolizumab in Gastric Cancer

Bassam Sonbol, MD, discusses the role of pembrolizumab in the treatment of patients with gastric cancer.

Bassam Sonbol, MD, an oncologist at Mayo Clinic Arizona, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with gastric cancer.

The role of the agent in the treatment of patients with gastric cancer has been examined over the last few years, according to Sonbol. Initially, use of pembrolizumab was limited to the third-line setting, but recently, the FDA’s Oncologic Drugs Advisory Committee voted against maintaining the accelerated approval of the agent for the treatment of patients with PD-L1–positive, recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of therapy, Sonbol says. 

In the frontline setting, pembrolizumab was also examined with or without chemotherapy vs chemotherapy alone in the phase 3 KEYNOTE-062 trial (NCT02494583), Sonbol notes. Overall, the study yielded negative results. Although pembrolizumab monotherapy was non-inferior to chemotherapy, it was also not superior. As such, it is not often utilized as a monotherapy, especially in patients who are microsatellite stable, Sonbol concludes. 

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.